Moveable walls and a stunning number of robotics at its sites in France and Singapore, among other features, has earned Sanofi international recognition for innovation.
- Prevascularized Bio-hybrid Organ Platforms Are Redefining Cell Therapy Delivery
- Dr. Peter Marks On Why Gene Therapy May Need A New Regulatory Playbook
- Can A Biotech Create A CDMO Market?
- Why Are Life Science Companies So Poorly Prepared For RIM's Future?
- April 2026 — CDMO Opportunities And Threats Report
- Cell And Gene Therapies: The Emerging Reality For Scalable Market Readiness
- Tackling The Cell & Gene Therapy Sector's Practical Post-Approval Problem
- Why Your MES RFP Is Failing Before It Starts
CELL & GENE ARTICLES, APP NOTES, CASE STUDIES, & WHITE PAPERS
-
When To Consider Material And Personnel Airlocks For Downflow Booths
Strategic use of airlocks in downflow booth design enhances pressure stability and containment. A risk-based approach ensures facility integration meets rigorous safety and compliance standards.
-
Manufacturing ADCs: Extractables In Single-Use Systems
Antibody-drug conjugates offer targeted cancer treatment with reduced toxicity. Discover how single-use technologies simplify ADC manufacturing to ensure safety, flexibility, and efficiency.
-
Enabling MSC Harvest, Wash, And Concentration
A study demonstrates how a low-shear, closed-system centrifuge achieved over 90% MSC recovery and minimized viability loss, supporting scalable cell therapy manufacturing.
-
Navigating CMC Regulation For Plasmid DNA In Gene Therapy
Explore how evolving regulatory pathways and CMC innovation are shaping the future of gene therapy and viral vector production, plus what to consider when selecting a CDMO partner.
-
Yeast Extracts: Improving Expression
Yeast extract improves E. coli protein production by over 50%, boosts desired protein attributes 4X, and offers a secure animal-free nutrient source.
-
The Proven, Practical Gateway To Upstream Process Intensification
N-1 perfusion enables higher inoculum densities, faster production, and reduced costs without altering fed-batch processes. Explore a practical path to intensification for biologics manufacturers.
-
AAV Viral Titering Using Nanoplate-Based Digital PCR
Examine how nanoplate-based digital PCR streamlines AAV titering, providing faster results and greater accuracy, advancing gene therapy development from the lab to the clinic.
-
Navigating The CGT Landscape: Key Takeaways From The FDA's New FAQ
The FDA's new FAQ on cell and gene therapy offers a roadmap for developers. Review key insights from the document, including the importance of early engagement with the FDA, CMC considerations, and more.
-
Shielded BSCs: Regulatory Requirement Or Risk-Based Engineering Solution?
Master the balance between USP <825> aseptic standards and radiation safety. Learn how integrated engineering solutions ensure regulatory compliance while protecting both patients and personnel.
-
Transforming PSP Enrollment To Enhance User Experiences And Optimize Workflows
Lengthy enrollment calls burden patients and PSP teams alike. See how a digital-first intake approach cut onboarding time and improved outcomes for everyone involved.
NEWSLETTER ARCHIVE
- 05.15.26 -- Sana, Mayo Clinic Advance A New Model For Cell Therapy Delivery In T1D
- 05.14.26 -- Discover critical components for fluid management and flow control
- 05.14.26 -- Early CDMO Engagement For Cell Therapies? CellProthera's CEO Thinks Not
- 05.13.26 -- Manufacturing Moves Shaping Advanced Therapies
- 05.13.26 -- How MTP Is Transforming Pharma Production Lines
- Dr. Peter Marks On Why Gene Therapy May Need A New Regulatory Playbook
- Regeneron Advances In Vivo Gene Therapy For Hearing Loss
- Sana, Mayo Clinic Advance A New Model For Cell Therapy Delivery In T1D
- Reprogramming T-Cell Access To Solid Tumors Through Improved Trafficking And Entry
- Target Selection Drives The Future Of CAR T Therapy In Solid Tumors
CELL AND GENE CONTENT COLLECTIONS
While there are opportunities to scale, there are also manufacturing gaps, capacity issues, and production timelines that require improvement to do so. And then, of course, there’s cost. Because scale up and scale out are significant to everyone in the sector, we’ve curated insightful editorial that addresses the most important aspects of scalability.
More Content Collections